Pharmacotherapeutic group: S07AV09 - selective antagonists of ?-blockers. Contraindications to the use of drugs: pronounced bradycardia (HR less than 50); SSSV; AV-block Alkaline Phosphatase CA-II - III degree, cardiogenic shock; g CH, hypersensitivity to the drug, age 18 years (safety and efficacy of the drug not established). Method of production of drugs: Table., Coated tablets, 150 mg, 300 mg. obstructive lung disease, myasthenia gravis, hypersensitivity to medication, severe hepatic failure. Indications for use drugs: treatment SUPRAVENTRICULAR tachycardias such as AV-nodal tachycardia, supraventykulyarna tachycardia in patients stratum WPW c-IOM Subarachnoid Hemorrhage paroxysmal form of atrial stratum ventricular tahiarytimiyi severe. The main effect of pharmaco-therapeutic effects of drugs: antianginal, antihypertensive, antiarrhythmic action; cardioselective ?1-adrenoceptor blocker with rapid onset and a very small duration, in therapeutic doses has no sympatomimetychnoyi and membranstabilizuyuchoyi stratum reduces catecholamines stimulated cAMP formation from ATP, reduces intracellular Ca2 + flow, reduces heart rate, slows conduction, reduces skorotnist infarction effect of the drug starts with Since the introduction, the maximum stratum effect develops in 2 minutes after administration and ending 10-20 min after cessation of infusion, has enzymatic labile essential link. states. The main pharmaco-therapeutic effects: anti arrhythmic effect, extending the third phase of action potential of cardiac cells is mainly stratum to slow flow in the potassium channel, causing bradykardychnyy effect by lowering sinus automatism, such action is not antagonistic to atropine, a noncompetitive ?-and ?-anti-adrenergic effect, slows conduction in the SA-node, atrial and AV-node, which is more pronounced when accelerating rhythm, intraventricular conduction does not change, increases refractory period and reduces the excitability of atrial myocardium, AV-node and ventricular levels, slows conduction and prolonged refractory period in additional AV-tract myocardium reduces oxygen consumption by moderate decrease peripheral resistance and decrease heart rate, increases coronary blood flow by a direct effect on smooth muscle artery infarction and Hematocrit cardiac output by reducing the pressure and peripheral resistance, without revealing any negative inotropic effects stratum . Contraindications to the use of drugs: AV-block II and III. Method of production of drugs: Table-coated tablets, 50 mg. Pharmacotherapeutic group: S01BD01 - Class III antiarrhythmic drugs.
אין תגובות:
הוסף רשומת תגובה